Monoclonal antibody drug conjugates in the treatment of cancer

Curr Opin Immunol. 1999 Oct;11(5):584-8. doi: 10.1016/s0952-7915(99)00012-6.

Abstract

Monoclonal antibodies directed to tumor-associated antigens have been chemically conjugated to drugs with different mechanisms of action and different levels of potency. Monoclonal-antibody-directed drug delivery has the potential to both improve efficacy and reduce systemic toxicity. Several immunoconjugates have demonstrated impressive antigen-specific antitumor activity in preclinical models. Phase I trials of a calicheamicin immunoconjugate for treatment of acute myeloid leukemia and a doxorubicin immunoconjugate for treatment of carcinoma have recently been completed.

Publication types

  • Review

MeSH terms

  • Antibiotics, Antineoplastic / administration & dosage*
  • Antineoplastic Agents / administration & dosage*
  • Drug Carriers
  • Humans
  • Immunoconjugates / administration & dosage*
  • Liposomes / immunology
  • Neoplasms / blood supply
  • Neoplasms / drug therapy*
  • Neovascularization, Pathologic / immunology

Substances

  • Antibiotics, Antineoplastic
  • Antineoplastic Agents
  • Drug Carriers
  • Immunoconjugates
  • Liposomes